May 21, 2021
Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR.
On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement aimed at addressing this clinical niche.
All three are manufactured by Edwards Lifesciences:
Thirty-day data from TRISCEND make the case for valve replacement, specifically with the Evoque device, in patients with symptomatic and at least moderate TR.